Please assess the completion status of the following clinical trial:

Trial Title: Point of Care Evaluation of Novir 2019-nCoV Immunoglobulin G/ Immunoglobulin M (IgG/IgM) Antibody Test (Collodial Gold)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Must be 21 years old or older.~* Must be able to provide finger stick and venous whole blood samples.~* Must be able to understand and sign a consent form.~* Must be able to provide an additional sample(s) required by the study site for an additional FDA EUA authorized antibody testing (ELISA, CMIA, or other antibody test).~* Has an immediate need to determine COVID-19 status for occupational purposes.~* Was exposed to a COVID-19 patient within 7 days that leads the healthcare provider to suspect the individual of possibly having SARS-CoV-2 infection.~* Has symptoms that lead the healthcare provider to suspect the individual of possibly having SARS-CoV-2 infection.~* Has had a positive FDA EUA authorized PCR test between 1-28 days with or without symptom expression.~* Individuals who have tested positive for COVID-19 infection and have antibodies detected must have agreed to participate in the MCW Tissue Bank COVID-19 banking project.~Exclusion Criteria:~* Is receiving treatment with infusion of convalescent plasma or other antibody therapy related to SARS-CoV-2 infections.~* Tested negative for COVID-19 by PCR more than 7 days ago.~* Is participating in a SARS-CoV-2 vaccine study.or received any doses of the available SARS-CoV-2 vaccines.~* Previously tested positive for COVID-19 at any point in time (for asymptomatic patients enrolling in the negative patient population).

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Antigen testing in those who have history of COVID-19 (Type: None): Individuals must have had history of COVID-19. Finger stick point of care test will be performed which results in 10 minutes indicating if there is detection of a control, IgG and IgM. Control line must be present for test to be considered valid. 3mL of venous whole blood will be collected from patient in which the research team will perform the SARS-CoV-2 antibody test.
- Antigen testing in those who do not have history of COVID-19 and COVID immunization (Type: None): Individuals may not have history of COVID-19 and COVID immunizations in order to be eligible. Finger stick point of care test will be performed which results in 10 minutes indicating if there is detection of a control, IgG and IgM. Control line must be present for test to be considered valid. 3mL of venous whole blood will be collected from patient in which the research team will perform the SARS-CoV-2 antibody test.

Based on this trial design, predict the completion outcome and termination type (if applicable).